Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
Lancet Oncol. 2020.
PMID: 31838010
Clinical Trial.
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer.
Luque M, Sanz-Álvarez M, Morales-Gallego M, Madoz-Gúrpide J, Zazo S, Domínguez C, Cazorla A, Izarzugaza Y, Arranz JL, Cristóbal I, Rojo F.
Luque M, et al. Among authors: izarzugaza y.
Cancers (Basel). 2022 Dec 8;14(24):6034. doi: 10.3390/cancers14246034.
Cancers (Basel). 2022.
PMID: 36551522
Free PMC article.
Review.
Item in Clipboard
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T.
Villacampa G, et al. Among authors: izarzugaza y.
Eur J Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. Epub 2022 Sep 5.
Eur J Cancer. 2022.
PMID: 36067616
Clinical Trial.
Item in Clipboard
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J.
Prat A, et al. Among authors: izarzugaza y.
Future Oncol. 2022 Oct 6. doi: 10.2217/fon-2022-0660. Online ahead of print.
Future Oncol. 2022.
PMID: 36200668
Review.
Item in Clipboard
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.
Sanz-Álvarez M, Luque M, Morales-Gallego M, Cristóbal I, Ramírez-Merino N, Rangel Y, Izarzugaza Y, Eroles P, Albanell J, Madoz-Gúrpide J, Rojo F.
Sanz-Álvarez M, et al. Among authors: izarzugaza y.
Int J Mol Sci. 2023 Dec 22;25(1):207. doi: 10.3390/ijms25010207.
Int J Mol Sci. 2023.
PMID: 38203378
Free PMC article.
Item in Clipboard
Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.
Manso L, Sanchez-Muñoz A, Calvo I, Izarzugaza Y, Plata J, Rodriguez C.
Manso L, et al. Among authors: izarzugaza y.
Breast Care (Basel). 2018 Aug;13(4):277-283. doi: 10.1159/000488794. Epub 2018 Jul 13.
Breast Care (Basel). 2018.
PMID: 30319330
Free PMC article.
Review.
Item in Clipboard
Cite
Cite